Phase 3 Schizophrenia Trial, Recruiting NCT06882785 Sponsor: Bristol-Myers Squibb Condition: Schizophrenia
Back to Schizophrenia

Phase 3 Schizophrenia Trial, Recruiting

NCT06882785
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must have been formally diagnosed with schizophrenia through a thorough psychiatric assessment, using recognised diagnostic guidelines (DSM-5), confirmed by a structured interview called the MINI.
  • Your symptoms must fall within a specific range on a standard schizophrenia rating scale called the PANSS, with a total score between 80 and 120 (confirm with trial site).
  • Your overall illness severity must be rated at least 4 (meaning "moderately ill") on a standard scale used by clinicians called the CGI-S (confirm with trial site).

Who may not be able to join:

  • You may not be eligible if you have been diagnosed with any other major psychiatric condition (besides schizophrenia) within the past 12 months.
  • You may not be eligible if you have only recently been diagnosed with schizophrenia or if this would be your first time receiving treatment for it.
  • You may not be eligible if you have any significant ongoing or past physical health conditions (confirm with trial site for details on what qualifies).
  • There are additional eligibility requirements set by the trial's rules that are not listed here, so further checks will be needed (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
10 June 2025
Est. completion
23 September 2028

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score; Number of participants with treatment-emergent adverse events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov